The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
Padmanabhan brings over two decades of extensive experience in FMCG sector
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
The product will be launched in Q1FY26
David joins HCTI with a distinguished career of over 22 years of corporate finance experience
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
_256_384.jpg)
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
The board of directors accepted Hrosz’s resignation and expressed appreciation for his significant contributions during his tenure
Subscribe To Our Newsletter & Stay Updated
